Two Seas Capital LP Has $60.55 Million Holdings in Arbutus Biopharma Corporation $ABUS

Two Seas Capital LP raised its stake in Arbutus Biopharma Corporation (NASDAQ:ABUS) by 14.5% in the 4th quarter, HoldingsChannel reports. The fund owned 12,589,158 shares of the biopharmaceutical company’s stock after buying an additional 1,597,897 shares during the quarter. Arbutus Biopharma accounts for about 1.2% of Two Seas Capital LP’s holdings, making the stock its 11th biggest holding. Two Seas Capital LP owned about 0.07% of Arbutus Biopharma worth $60,554,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its position in Arbutus Biopharma by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 3,677,307 shares of the biopharmaceutical company’s stock valued at $17,691,000 after acquiring an additional 11,145 shares in the last quarter. ADAR1 Capital Management LLC grew its position in shares of Arbutus Biopharma by 2.7% during the 3rd quarter. ADAR1 Capital Management LLC now owns 2,903,226 shares of the biopharmaceutical company’s stock worth $13,181,000 after buying an additional 77,453 shares during the period. Adage Capital Partners GP L.L.C. grew its position in shares of Arbutus Biopharma by 63.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,575,941 shares of the biopharmaceutical company’s stock worth $7,960,000 after buying an additional 1,000,000 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Arbutus Biopharma by 290.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,075,948 shares of the biopharmaceutical company’s stock worth $7,245,000 after buying an additional 1,544,070 shares during the period. Finally, Bank of America Corp DE boosted its stake in Arbutus Biopharma by 21.1% during the 3rd quarter. Bank of America Corp DE now owns 1,450,822 shares of the biopharmaceutical company’s stock worth $6,587,000 after acquiring an additional 253,167 shares during the last quarter. Institutional investors and hedge funds own 43.79% of the company’s stock.

Arbutus Biopharma Stock Down 2.3%

Shares of ABUS stock opened at $4.25 on Friday. The company’s fifty day simple moving average is $4.38 and its 200-day simple moving average is $4.41. The firm has a market cap of $839.55 million, a PE ratio of 5.12 and a beta of 0.63. Arbutus Biopharma Corporation has a 12 month low of $3.04 and a 12 month high of $5.10.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported $0.87 EPS for the quarter. The business had revenue of $179.13 million for the quarter. Arbutus Biopharma had a net margin of 83.95% and a return on equity of 129.32%. On average, equities analysts predict that Arbutus Biopharma Corporation will post -0.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ABUS. Wall Street Zen raised shares of Arbutus Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arbutus Biopharma in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $5.00.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.